ARPC1B

Across TCGA pan-cancer cohorts, ARPC1B mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARPC1B’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ARPC1B mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types ARPC1B is over-expressed in tumor.

CCRCC, HNSC, and COAD are the cancer types where ARPC1B tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARPC1B mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	II,III,IV	+0.584	<.001	11	view →
HNSC	Male	IV	+0.532	<.001	11	view →
COAD	Female	III,IV	+0.477	<.001	9	view →
PDAC	Female	All	+0.853	<.001	8	view →
LUAD	Female	All	+0.238	<.001	8	view →
OV	All	All	+0.764	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARPC1B–CCRCC

Open the CCRCC breakdown →